vs

Side-by-side financial comparison of Royalty Pharma plc (RPRX) and Utz Brands, Inc. (UTZ). Click either name above to swap in a different company.

Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $341.0M, roughly 1.8× Utz Brands, Inc.). Royalty Pharma plc runs the higher net margin — 34.4% vs 0.7%, a 33.8% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs -3.1%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -1.5%).

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

Utz Brands, Inc., more commonly known as Utz, is an American snack food company based in Hanover, Pennsylvania. The company produces a variety of potato chips, pretzels, and other snacks, with most products sold under their family of brands. Utz is also a snack supplier to warehouse clubs and merchandisers.

RPRX vs UTZ — Head-to-Head

Bigger by revenue
RPRX
RPRX
1.8× larger
RPRX
$622.0M
$341.0M
UTZ
Growing faster (revenue YoY)
RPRX
RPRX
+7.9% gap
RPRX
4.8%
-3.1%
UTZ
Higher net margin
RPRX
RPRX
33.8% more per $
RPRX
34.4%
0.7%
UTZ
Faster 2-yr revenue CAGR
RPRX
RPRX
Annualised
RPRX
4.6%
-1.5%
UTZ

Income Statement — Q4 FY2025 vs Q4 FY2024

Metric
RPRX
RPRX
UTZ
UTZ
Revenue
$622.0M
$341.0M
Net Profit
$214.2M
$2.3M
Gross Margin
25.5%
Operating Margin
62.4%
2.1%
Net Margin
34.4%
0.7%
Revenue YoY
4.8%
-3.1%
Net Profit YoY
2.9%
108.3%
EPS (diluted)
$0.49
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RPRX
RPRX
UTZ
UTZ
Q4 25
$622.0M
Q3 25
$609.3M
Q2 25
$578.7M
Q1 25
$568.2M
Q4 24
$593.6M
$341.0M
Q3 24
$564.7M
$365.5M
Q2 24
$537.3M
$356.2M
Q1 24
$568.0M
$346.5M
Net Profit
RPRX
RPRX
UTZ
UTZ
Q4 25
$214.2M
Q3 25
$288.2M
Q2 25
$30.2M
Q1 25
$238.3M
Q4 24
$208.2M
$2.3M
Q3 24
$544.0M
$-2.2M
Q2 24
$102.0M
$19.8M
Q1 24
$4.8M
$-4.0M
Gross Margin
RPRX
RPRX
UTZ
UTZ
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
25.5%
Q3 24
26.9%
Q2 24
26.7%
Q1 24
25.5%
Operating Margin
RPRX
RPRX
UTZ
UTZ
Q4 25
62.4%
Q3 25
70.1%
Q2 25
36.3%
Q1 25
94.0%
Q4 24
60.9%
2.1%
Q3 24
5.3%
Q2 24
50.2%
6.3%
Q1 24
-13.0%
2.8%
Net Margin
RPRX
RPRX
UTZ
UTZ
Q4 25
34.4%
Q3 25
47.3%
Q2 25
5.2%
Q1 25
41.9%
Q4 24
35.1%
0.7%
Q3 24
96.3%
-0.6%
Q2 24
19.0%
5.6%
Q1 24
0.8%
-1.2%
EPS (diluted)
RPRX
RPRX
UTZ
UTZ
Q4 25
$0.49
Q3 25
$0.67
Q2 25
$0.07
Q1 25
$0.55
Q4 24
$0.46
$0.04
Q3 24
$1.21
$-0.03
Q2 24
$0.23
$0.23
Q1 24
$0.01
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RPRX
RPRX
UTZ
UTZ
Cash + ST InvestmentsLiquidity on hand
$618.7M
$56.1M
Total DebtLower is stronger
$9.0B
$768.6M
Stockholders' EquityBook value
$9.7B
$696.9M
Total Assets
$19.6B
$2.7B
Debt / EquityLower = less leverage
0.92×
1.10×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RPRX
RPRX
UTZ
UTZ
Q4 25
$618.7M
Q3 25
$938.9M
Q2 25
$631.9M
Q1 25
$1.1B
Q4 24
$929.0M
$56.1M
Q3 24
$950.1M
$64.9M
Q2 24
$1.8B
$66.6M
Q1 24
$843.0M
$47.0M
Total Debt
RPRX
RPRX
UTZ
UTZ
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
$768.6M
Q3 24
$7.6B
$780.8M
Q2 24
$7.6B
$797.6M
Q1 24
$6.1B
$756.9M
Stockholders' Equity
RPRX
RPRX
UTZ
UTZ
Q4 25
$9.7B
Q3 25
$9.6B
Q2 25
$9.5B
Q1 25
$9.8B
Q4 24
$10.3B
$696.9M
Q3 24
$10.3B
$685.7M
Q2 24
$9.8B
$686.0M
Q1 24
$9.9B
$671.1M
Total Assets
RPRX
RPRX
UTZ
UTZ
Q4 25
$19.6B
Q3 25
$19.3B
Q2 25
$18.3B
Q1 25
$17.6B
Q4 24
$18.2B
$2.7B
Q3 24
$18.0B
$2.6B
Q2 24
$17.7B
$2.7B
Q1 24
$16.1B
$2.6B
Debt / Equity
RPRX
RPRX
UTZ
UTZ
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
1.10×
Q3 24
0.74×
1.14×
Q2 24
0.78×
1.16×
Q1 24
0.62×
1.13×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RPRX
RPRX
UTZ
UTZ
Operating Cash FlowLast quarter
$827.1M
$54.2M
Free Cash FlowOCF − Capex
$16.5M
FCF MarginFCF / Revenue
4.8%
Capex IntensityCapex / Revenue
11.1%
Cash ConversionOCF / Net Profit
3.86×
23.67×
TTM Free Cash FlowTrailing 4 quarters
$7.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RPRX
RPRX
UTZ
UTZ
Q4 25
$827.1M
Q3 25
$702.6M
Q2 25
$364.0M
Q1 25
$596.1M
Q4 24
$742.5M
$54.2M
Q3 24
$703.6M
$52.2M
Q2 24
$658.2M
$8.9M
Q1 24
$664.6M
$-9.1M
Free Cash Flow
RPRX
RPRX
UTZ
UTZ
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$16.5M
Q3 24
$29.1M
Q2 24
$-15.3M
Q1 24
$-22.7M
FCF Margin
RPRX
RPRX
UTZ
UTZ
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
4.8%
Q3 24
8.0%
Q2 24
-4.3%
Q1 24
-6.5%
Capex Intensity
RPRX
RPRX
UTZ
UTZ
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
11.1%
Q3 24
6.3%
Q2 24
6.8%
Q1 24
3.9%
Cash Conversion
RPRX
RPRX
UTZ
UTZ
Q4 25
3.86×
Q3 25
2.44×
Q2 25
12.06×
Q1 25
2.50×
Q4 24
3.57×
23.67×
Q3 24
1.29×
Q2 24
6.45×
0.45×
Q1 24
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

UTZ
UTZ

Segment breakdown not available.

Related Comparisons